CytomX Therapeutics ROA 2014-2022 | CTMX
Current and historical return on assets (ROA) values for CytomX Therapeutics (CTMX) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| CytomX Therapeutics ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2022-09-30 |
$-0.10B |
$0.23B |
-34.58% |
| 2022-06-30 |
$-0.10B |
$0.26B |
-30.62% |
| 2022-03-31 |
$-0.09B |
$0.30B |
-26.12% |
| 2021-12-31 |
$-0.08B |
$0.34B |
-21.73% |
| 2021-09-30 |
$-0.07B |
$0.37B |
-18.65% |
| 2021-06-30 |
$-0.07B |
$0.40B |
-16.56% |
| 2021-03-31 |
$-0.06B |
$0.43B |
-15.80% |
| 2020-12-31 |
$-0.03B |
$0.36B |
-8.65% |
| 2020-09-30 |
$-0.05B |
$0.38B |
-13.89% |
| 2020-06-30 |
$-0.06B |
$0.40B |
-16.23% |
| 2020-03-31 |
$-0.08B |
$0.44B |
-19.54% |
| 2019-12-31 |
$-0.10B |
$0.34B |
-26.09% |
| 2019-09-30 |
$-0.10B |
$0.37B |
-23.57% |
| 2019-06-30 |
$-0.10B |
$0.41B |
-21.90% |
| 2019-03-31 |
$-0.08B |
$0.45B |
-18.62% |
| 2018-12-31 |
$-0.08B |
$0.46B |
-19.61% |
| 2018-09-30 |
$-0.05B |
$0.48B |
-12.24% |
| 2018-06-30 |
$-0.04B |
$0.38B |
-9.62% |
| 2018-03-31 |
$-0.05B |
$0.38B |
-12.95% |
| 2017-12-31 |
$-0.04B |
$0.40B |
-12.78% |
| 2017-09-30 |
$-0.06B |
$0.39B |
-20.43% |
| 2017-06-30 |
$-0.06B |
$0.35B |
-26.90% |
| 2017-03-31 |
$-0.05B |
$0.18B |
-26.25% |
| 2016-12-31 |
$-0.06B |
$0.20B |
-29.84% |
| 2016-09-30 |
$-0.06B |
$0.19B |
-28.90% |
| 2016-06-30 |
$-0.06B |
$0.21B |
-31.62% |
| 2016-03-31 |
$-0.05B |
$0.19B |
-39.69% |
| 2015-12-31 |
$-0.04B |
$0.20B |
-53.42% |
| 2015-06-30 |
$-0.02B |
$0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.115B |
$0.070B |
|
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|
